PRKAA1

Overview

PRKAA1 encodes the catalytic alpha-1 subunit of AMP-activated protein kinase (AMPK), a central cellular energy sensor that helps maintain metabolic homeostasis. AMPK is activated when cellular energy is low and coordinates adaptive responses that promote ATP-generating processes while restraining energy-consuming pathways. Through this role, PRKAA1 is biologically linked to regulation of glucose and lipid metabolism, mitochondrial function, autophagy, inflammation, and stress adaptation.

In biomedical research, PRKAA1 is frequently discussed in the context of diseases and processes shaped by metabolic stress, including cancer, liver disease, adipocyte catabolism, myocardial ischemia/reperfusion injury, neuroinflammation, aging, and autophagy-related disorders. It is also a recurring target in studies of natural products, small-molecule modulators, and pathway-based therapies that intersect with PI3K/AKT/mTOR, sirtuin 1, TGF-β/Smad, and PD-1/PD-L1 signaling.

Focus of Latest Publications

Recent publications have continued to place PRKAA1, the catalytic subunit of AMP-activated protein kinase (AMPK), at the center of studies on metabolic regulation, inflammation, cancer, and neuroprotection. Several reports examined PRKAA1 as part of AMPK signaling in response to small molecules or nutritional interventions, including metformin, berberine, sophoricoside, and maternal broccoli powder intake. Across these studies, PRKAA1-associated AMPK activation was linked to improved glucose homeostasis, reduced inflammatory signaling, altered autophagy, and changes in tissue-specific metabolic programs.

In diabetic encephalopathy, a berberine-metformin combination was evaluated in streptozotocin-nicotinamide diabetic rats using Chou-Talalay synergy analysis, hippocampal mechanistic assays, and LC-MS/MS pharmacokinetic verification. The combination restored recognition memory and showed supra-additive effects, with AMPK activation and Nrf2-related antioxidant signaling discussed as correlates of the neuroprotective response. The authors reported that the pharmacokinetic data supported a pharmacodynamic basis for the interaction rather than altered drug exposure. In a separate rat study, maternal broccoli powder intake during lactation increased AMPK phosphorylation in the liver and hypothalamus of offspring programmed by maternal protein restriction, while reducing inflammatory markers and lowering mTOR and Akt phosphorylation in the liver.

PRKAA1 was also implicated in cancer-related AMPK signaling. In hepatocellular carcinoma models, sophoricoside increased AMPK phosphorylation, suppressed proliferation, migration, and invasion, and reduced tumor growth in xenografts; these effects were reversed by the AMPK inhibitor compound C, supporting AMPK dependence. In pancreatic ductal adenocarcinoma, irinotecan-induced early AMPK activation was described as part of a sequence leading to autophagy and fatty acid oxidation that contributed to acquired drug resistance, and inhibition of fatty acid oxidation blocked autophagy flux and tumor regrowth. Another study identified SLC5A11 as a mediator of metformin-induced PD-L1 suppression through AMPK-dependent signaling, linking PRKAA1-associated pathways to enhanced anti-PD-1 immunotherapy responses in lung and pancreatic cancer models.

Additional recent work expanded the context of PRKAA1-linked AMPK biology to adipose tissue and thermogenesis. One study identified a nutrient-responsive AMPK/TBK1 feedback circuit in adipocytes, showing that AMPK activation induced Tbk1 transcription and that dual targeting of TBK1 and AMPK enhanced weight loss and improved metabolic outcomes in mice. Another report described Feimin as an AMPK-phosphorylated factor that translocates to the nucleus during cold exposure and cooperates with PGC1α to drive thermogenic gene expression, whereas obesity impaired this phosphorylation and nuclear localization. Together, these publications reinforce PRKAA1 as a recurring target in studies of energy sensing, inflammation, and disease-modifying interventions.

Key Publications

• NEWJul Supra-additive neuroprotective effects of berberine-metformin combination in diabetic encephalopathy: Chou-Talalay synergy quantification, AMPK-Nrf2 axis modulation, and pharmacokinetic verification. (Metabolic brain disease, 2026, PMID 42390621): "Berberine and metformin independently activate AMPK and may engage Nrf2-mediated antioxidant defenses, yet their combined neuroprotective interaction has not been formally quantified using validated synergy frameworks, nor has its pharmacokinetic basis been verified."
• May A nutrient-responsive AMPK/TBK1 circuit restricts adipocyte catabolism. (JCI insight, 2026, PMID 42100877): "We identified TANK binding kinase 1 (TBK1) as a nutrient- and inflammation-responsive brake on AMPK signaling in adipocytes."
• May Cellular Feimin promotes cold-induced thermogenesis. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42066046): "Here, we identify Feimin as a key activator of adaptive thermogenesis that connects AMP-activated protein kinase (AMPK) signaling to nuclear transcriptional regulation in adipose tissue."
• Apr Maternal broccoli powder intake during lactation alters inflammatory status and modulates AMPK phosphorylation in the liver and hypothalamus of female weaning rats programmed by maternal protein restriction. (Journal of developmental origins of health and disease, 2026, PMID 42036778): "In conclusion, maternal BP intake during lactation decreased inflammation and increased AMPK phosphorylation in the liver and hypothalamus of weaning rats programmed by maternal undernutrition."
• May Activation of AMPK by Sophoricoside Suppresses Primary Liver Cancer Progression In Vitro and In Vivo. (Journal of biochemical and molecular toxicology, 2026, PMID 42003007): "SOP increased AMPK phosphorylation (Thr172; +2.5-fold at 300 μM) without affecting total AMPK."
• Jul Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. (Cancer research, 2026, PMID 42008004): "Initially, DNA damage activated AMPK, inducing early autophagy within 24 hours that fueled fatty acid oxidation (FAO), boosting ATP production."
• Apr Neuroinflammation, Autophagy, and Neurodegeneration: Mechanisms and Therapeutic Insights. (CNS & neurological disorders drug targets, 2026, PMID 41918200): "we focus on critical pathways, including mTOR and AMPK, that regulate these events and illustrate how their dysregulation may lead to a vicious cycle of inflammation and autophagy dysfunction."
• Apr Mechanistic insights into aging and longevity: Implications for ovarian function and health. (Tissue & cell, 2026, PMID 41833148): "Key mechanistic contributors include telomere attrition, accumulated DNA damage, impaired autophagy, chronic inflammation, and dysregulation of major longevity pathways such as PI3K/AKT/mTOR, AMPK, and sirtuins."
• Apr Mechanistic Modulation of Autophagy by Bioactive Natural Products: Implications for Human Aging and Longevity. (Nutrients, 2026, PMID 41830033): "Mechanistically, these compounds regulate autophagy by modulating key signaling pathways, such as AMPK, PI3K/AKT/mTOR, SIRT1, and FOXO, while also alleviating oxidative stress, inflammation, and mitochondrial dysfunction."
• May Cannabisin A and B from hemp seed hulls improve glucose homeostasis by re-engaging insulin, leptin, and AMPK pathways via selective PTP1B inhibition. (Phytomedicine : international journal of phytotherapy and phytopharmacology, 2026, PMID 41831381): "However, natural compounds capable of simultaneously inhibiting PTP1B and stimulating AMPK-the two major metabolic control nodes-remain scarce."